Evidence map›Paper›PMID 40827443›Full record

ArticleCancer medicine2025

Global Burden of Hepatoblastoma From 1990 to 2021 and Projection to 2030.

Xiaoyu Huang, Zhiqiang Zhang, Qiong Wu, Shaoyang Kang, Xinyue Yang, Fengmei Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xiaoyu HuangSchool of Medicine, Nankai University, Tianjin, China.ORCID https://orcid.org/0000-0002-1002-1759
Zhiqiang ZhangGraduate School of Tianjin Medical University, Tianjin Medical University, Tianjin, China.
Qiong WuSchool of Medicine, Nankai University, Tianjin, China.
Shaoyang KangSchool of Medicine, Nankai University, Tianjin, China.
Xinyue YangGraduate School of Tianjin Medical University, Tianjin Medical University, Tianjin, China.
Fengmei WangDepartment of Gastroenterology and Hepatology, Tianjin Key Laboratory of Molecular Diagnosis and Treatment of Liver Cancer, Tianjin First Central Hospital, Nankai University, Tianjin, China.

Funding

Tianjin Health Science and Technology Project TJWJ2022XK027
6 · The paper itself

Abstract

backgroundHepatoblastoma (HB) is the most common primary pediatric hepatocellular carcinoma, and the five-year survival rate for HB is the lowest among childhood cancers, as 20% of cases are chemotherapy resistant or unresectable. Understanding the global burden of HB and future trends in HB burden is urgently needed for gastroenterology and hepatology specialists and pediatricians. This study aims to provide a comprehensive assessment of the global burden of hepatoblastoma, predict future trends over the next decade, and offer insights into its management.

methodsUsing data from the Global Burden of Disease 2021, trends in HB-related mortality and disability-adjusted life years (DALYs) were analyzed. Age-standardized rates (ASR) and estimated annual percentage changes (EAPC) were employed to measure trends in these outcomes. Joinpoint regression identified trends, while Bayesian age-period-cohort (BAPC) modeling projected the future burden.

resultsAlthough the global number of HB-related deaths decreased from 1990 to 2021, the number of deaths in 2021 in low socio-demographic index (SDI) regions remained comparable to 1990 levels, with a notable upward trend in 27 countries, particularly in West Africa. Mortality and DALYs rates were highest in the early neonatal period, with the 2-4 years age group also showing the greatest burden. Projections indicate a global decline in HB burden from 2021 to 2030, but regions such as West Africa are likely to face persistent challenges.

conclusionsIn light of rapid population growth and escalating poverty in Africa, early screening and intervention for hepatoblastoma, particularly among children under five in low SDI regions, are critical to reducing the disease burden. These findings have significant implications for liver health policy, emphasizing the need for targeted interventions based on age and region to mitigate the impact of hepatoblastoma.

Indexed as

Global Burden of DiseaseHepatoblastomaLiver NeoplasmsAdolescentBayes TheoremChildChild, PreschoolDisability-Adjusted Life YearsFemaleGlobal HealthHumansInfantInfant, NewbornMaleBayesian age‐period‐cohort modelingglobal burdenhepatoblastomapediatric populationprediction

Identifiers

PMID40827443
PMCPMC12361928

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.